Neuroplasticity in Parkinson’s disease

• Published in: Journal of Neural Transmission 2024-11, Vol.131 (11), p.1329-1339
• Main Authors: Popescu, Bogdan Ovidiu, Batzu, Lucia, Ruiz, Pedro J. Garcia, Tulbă, Delia, Moro, Elena, Santens, Patrick
• Format: Article
• Language: English
• Subjects: Medicine; Medicine & Public Health; Neurology; Neurology and Preclinical Neurological Studies - Review; Neurology and Preclinical Neurological Studies - Review Article; Neurosciences; Psychiatry
• ISSN: 0300-9564; 1435-1463; 1435-1463
• DOI: 10.1007/s00702-024-02813-y

Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder, affecting millions of people and rapidly increasing over the last decades. Even though there is no intervention yet to stop the neurodegenerative pathology, many efficient treatment methods are available, including for patients with advanced PD. Neuroplasticity is a fundamental property of the human brain to adapt both to external changes and internal insults and pathological processes. In this paper we examine the current knowledge and concepts concerning changes at network level, cellular level and molecular level as parts of the neuroplastic response to protein aggregation pathology, synapse loss and neuronal loss in PD. We analyse the beneficial, compensatory effects, such as augmentation of nigral neurons efficacy, as well as negative, maladaptive effects, such as levodopa-induced dyskinesia. Effects of physical activity and different treatments on neuroplasticity are considered and the opportunity of biomarkers identification and use is discussed.